AU2004283756B2 - Therapeutic use of methionine for the treatment or prevention of mucositis - Google Patents

Therapeutic use of methionine for the treatment or prevention of mucositis Download PDF

Info

Publication number
AU2004283756B2
AU2004283756B2 AU2004283756A AU2004283756A AU2004283756B2 AU 2004283756 B2 AU2004283756 B2 AU 2004283756B2 AU 2004283756 A AU2004283756 A AU 2004283756A AU 2004283756 A AU2004283756 A AU 2004283756A AU 2004283756 B2 AU2004283756 B2 AU 2004283756B2
Authority
AU
Australia
Prior art keywords
methionine
platinum
radiation
set forth
cddp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004283756A
Other languages
English (en)
Other versions
AU2004283756A2 (en
AU2004283756A1 (en
Inventor
Kathleen C. M. Campbell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Southern Illinois University Edwardsville
Original Assignee
Southern Illinois University System
Southern Illinois University Edwardsville
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern Illinois University System, Southern Illinois University Edwardsville filed Critical Southern Illinois University System
Publication of AU2004283756A2 publication Critical patent/AU2004283756A2/en
Publication of AU2004283756A1 publication Critical patent/AU2004283756A1/en
Application granted granted Critical
Publication of AU2004283756B2 publication Critical patent/AU2004283756B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2004283756A 2003-10-27 2004-10-27 Therapeutic use of methionine for the treatment or prevention of mucositis Ceased AU2004283756B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/694,436 2003-10-27
US10/694,436 US20050090551A1 (en) 2003-10-27 2003-10-27 Therapeutic use of methionine for the treatment or prevention of mucositis
PCT/US2004/035626 WO2005039554A2 (en) 2003-10-27 2004-10-27 Therapeutic use of methionine for the treatment or prevention of mucositis

Publications (3)

Publication Number Publication Date
AU2004283756A2 AU2004283756A2 (en) 2005-05-06
AU2004283756A1 AU2004283756A1 (en) 2005-05-06
AU2004283756B2 true AU2004283756B2 (en) 2010-07-29

Family

ID=34522601

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004283756A Ceased AU2004283756B2 (en) 2003-10-27 2004-10-27 Therapeutic use of methionine for the treatment or prevention of mucositis

Country Status (8)

Country Link
US (1) US20050090551A1 (https=)
EP (1) EP1677775B1 (https=)
JP (1) JP4884974B2 (https=)
AT (1) ATE536178T1 (https=)
AU (1) AU2004283756B2 (https=)
CA (1) CA2543870C (https=)
ES (1) ES2376102T3 (https=)
WO (1) WO2005039554A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7071230B2 (en) * 1997-10-02 2006-07-04 Board Of Trustees Of Southern Illinois University Therapeutic use of D-methionine to reduce the toxicity of noise
US20070231377A1 (en) * 2006-03-28 2007-10-04 Novus International Inc. Compositions for promoting hair growth
GB0704718D0 (en) * 2007-03-12 2007-04-18 Prendergast Patrick T Compounds and methods for preventing and treating mucositis
WO2009094172A2 (en) 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
JP2011514349A (ja) 2008-03-07 2011-05-06 サイドース・エルエルシー フルベストラント配合物
KR20120041740A (ko) * 2009-09-14 2012-05-02 가부시키가이샤 시세이도 자외선 장해 경감 조성물
CN102481277A (zh) * 2009-09-30 2012-05-30 株式会社资生堂 紫外线损伤减轻口服组合物
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US8476310B2 (en) 2009-10-19 2013-07-02 Scidose Llc Docetaxel formulations with lipoic acid
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
JP5578997B2 (ja) * 2010-09-16 2014-08-27 国立大学法人 大分大学 がん化学療法誘発脱毛に対する抗脱毛用組成物
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
CN112839663A (zh) * 2018-08-14 2021-05-25 托斯克公司 降低氟尿嘧啶诱发的毒性的方法和组合物
US11446303B2 (en) 2019-06-21 2022-09-20 Tosk, Inc. Uridine phosphorylase (UPase) inhibitors for treatment of liver conditions
WO2022010778A1 (en) 2020-07-07 2022-01-13 Tosk, Inc. Uridine phosphorylase inhibitors to treat or prevent pulmonary disease
CN114051974B (zh) * 2021-11-10 2023-01-17 广西医科大学 一种肝癌模型及其构建方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003045334A2 (en) * 2001-11-29 2003-06-05 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652290A (en) * 1970-08-10 1972-03-28 Merck & Co Inc Beverages containing stabilized vitamin c
US3962429A (en) * 1973-08-01 1976-06-08 Chugai Seiyaku Kabushiki Kaisha Method for reducing side effects of aminoglycoside antibiotics and composition therefor
US4961926A (en) * 1987-11-19 1990-10-09 Sloan-Kettering Institute For Cancer Research Methods for prevention and treatment of mucositis with granulocyte colony stimulating factor
US5122369A (en) * 1990-03-30 1992-06-16 Harmony Health Products, Inc. Nutrient composition for preventing hair loss
AU703079B2 (en) * 1994-07-01 1999-03-11 Procter & Gamble Company, The Desquamation compositions
JPH08190187A (ja) * 1995-01-11 1996-07-23 Canon Inc 情報記録装置
US5667791A (en) * 1996-05-31 1997-09-16 Thione International, Inc. X-ray induced skin damage protective composition
US6187817B1 (en) * 1996-10-03 2001-02-13 Southern Illinois University School Of Medicine Therapeutic use of d-methionine to reduce the toxicity of platinum-containing anti-tumor compounds
EP0930877B1 (en) * 1996-10-03 2006-04-19 Southern Illinois University D-methionine to reduce the toxicity of platinum-containing anti-tumor compounds
ES2338946T3 (es) * 1998-02-13 2010-05-13 Nutramax Laboratories, Inc. Agentes y procedimientos para la proteccion, tratamiento y reparacion del tejido conjuntivo.
DK1194161T3 (da) * 1999-07-13 2006-02-13 Biovitrum Ab Stabile faktor VIII-sammensatninger
AU2002249863A1 (en) * 2000-10-24 2002-08-12 Diatide, Inc. Stabilization of radiopharmaceutical compositions using hydrophilic thioether or a hydrophilic 6-hydroxy chroman
MXPA03004546A (es) * 2000-11-22 2003-09-10 Rxkinetix Inc Tratamiento de mucositis.
PL363426A1 (en) * 2001-03-09 2004-11-15 Societe Des Produits Nestle S.A. Composition improving age-related physiological deficits and increasing longevity
US20040198841A1 (en) * 2003-03-13 2004-10-07 Oregon Health & Science University Use of thiol-based compositions in ameliorating mucosal injury
CA2581076A1 (en) * 2004-09-14 2006-03-23 Molecular Therapeutics, Inc. D-methionine formulation with improved biopharmaceutical properties

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003045334A2 (en) * 2001-11-29 2003-06-05 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy

Also Published As

Publication number Publication date
ATE536178T1 (de) 2011-12-15
ES2376102T3 (es) 2012-03-09
EP1677775B1 (en) 2011-12-07
US20050090551A1 (en) 2005-04-28
JP2007509955A (ja) 2007-04-19
AU2004283756A2 (en) 2005-05-06
EP1677775A2 (en) 2006-07-12
AU2004283756A1 (en) 2005-05-06
CA2543870A1 (en) 2005-05-06
CA2543870C (en) 2013-03-12
JP4884974B2 (ja) 2012-02-29
WO2005039554A2 (en) 2005-05-06
WO2005039554A3 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
US6187817B1 (en) Therapeutic use of d-methionine to reduce the toxicity of platinum-containing anti-tumor compounds
Campbell et al. D-methionine provides excellent protection from cisplatin ototoxicity in the rat
AU2004283756B2 (en) Therapeutic use of methionine for the treatment or prevention of mucositis
US8309560B2 (en) Methods and compositions for ameliorating the undesirable effects of chemotherapy
Teicher et al. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo
AU5193599A (en) Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
US20090247479A1 (en) Therapeutic Use of Methionine to Reduce the Toxicity of Aminoglycoside Antibiotics
EP0930877B1 (en) D-methionine to reduce the toxicity of platinum-containing anti-tumor compounds
WO1992002221A1 (en) Use of 2-phenyl-1,2-benzisoselenazol-3(2h)-one
US20070105782A1 (en) Protectant Combinations for Reducing Toxicities
Ginopoulos et al. A phase II study with paclitaxel and gemsitabine in the treatment of patients with stage IIIB-IV non small cell lung cancer (NSCLC)
Behera et al. Gemcitabine chemotherapy in NSCLC experience from India
MXPA01001065A (es) Uso de l-carnitina y sus derivados alcanoilo en la preparacion de medicamentos con actividad contra el cancer

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT( S) FILED 27 APR 2006

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired